Jan Medical’s Nautilus Neurowave Platform Could Be a Game-Changer for Quickly Identifying Stroke and Other Brain Abnormalities

This can join the fourteen other options for your clinics and ERs to diagnose a stroke properly. You'll have to let your medical team know about these options if you want them available in any reasonable timeframe.
http://www.onemedplace.com/blog/archives/12674
Dr. Lovoi has more than 30 years of experience managing and starting  innovative companies. Prior to founding Jan Medical, he was co-founder, prime inventor and CEO of Xoft Inc., a company focused on using tiny x-ray tubes to treat cancer. Xoft’s AXXENT® cancer treatment product is FDA-cleared for breast, endometrial, rectal and skin cancer treatment.  In addition to Jan Medical and Xoft, Dr. Lovoi founded Candescent Technologies, a flat panel display company; and INTA, a high temperature materials company. Dr. Lovoi has 50 patents issued and 20 pending applications. He has a Ph.D. in physics from the University of New Mexico (his research was conducted at Los Alamos National Laboratory) and has completed the Stanford Executive MBA program.
While Jan Medical’s Nautilus NeuroWave system is designed to address all areas of stroke, and ultimately traumatic brain injury, the company’s initial focus is detection and monitoring of vasospasm after subarachnoid hemorrhagic stroke and determination of ischemic stroke in the critical first few hours post-event.
Vasospasms are a serious complication for survivors of hemorrhagic stroke. Severe vasospasms can cause a second stroke when a brain vessel becomes constricted such that blood flow is severely restricted or even prevented from flowing beyond the constriction. Existing protocols for patients who survive an initial subarachnoid hemorrhagic stroke caused by bleeding into the space surrounding the brain call for monitoring for vasospasm for up to 21 days in a Neuro Critical Care Unit (NCCU).

More at the link